During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Eunice Wang, Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked: Why could IMGN632, a novel CD123-targeting antibody-drug conjugate, be an important treatment option for acute myeloid leukemia?
Eunice Wang discusses the results from the phase Ib study that explored the potent IMGN632 antibody-drug conjugate in patients with AML. She discusses the toxicity and safety profile of the agent and states the recommended dose. She also talks about the efficacy of this antibody-drug conjugate in the high-risk patient population.